Inflammatory bowel diseases (IBD) are characterized by chronic intestinal inflammation and epithelial barrier dysfunction, and their treatment relies on anti-inflammatory and immunomodulatory drugs. However, the molecular mechanisms underlying epithelial responses to these therapies remain incompletely understood, particularly at the proteome level. In this study, we applied label-free quantitative proteomics to investigate drug-induced molecular responses in cytokine-stimulated Caco-2 cells treated with mesalazine, prednisolone, or 6-mercaptopurine. We focused on both proteins from lysates and supernatant proteins. Across all treatments, proteomic profiling revealed alterations in pathways related to immune regulation, metabolism, oxidative stress response, and epithelial barrier remodeling. In addition to suppressing inflammatory signaling, drug treatment induced adaptive cellular responses characterized by modulation of energy metabolism, stress resistance and protein biosynthesis. In lysate samples, proteins associated with apoptosis inhibition, immunoproteasome activity, and epithelial integrity were frequently upregulated under treatment, while cytokine-response and inflammatory regulators were reduced. In the supernatants, a general decrease in proteins linked to immune activation, lipid metabolism, and extracellular matrix remodeling was observed, together with barrier-related and wound-healing proteins. Although several barrier-associated proteins were regulated, barrier breakdown in cytokine-stimulated samples could not be directly concluded from proteomic data alone, highlighting the importance of additional readouts. Comparison with previously generated data from monocyte-derived macrophages revealed cell type–specific drug responses and pointed out the metabolic and adaptive nature of epithelial cell regulation. Overall, this study demonstrates that proteomics provides valuable insights into drug-induced epithelial cell adaptation under inflammatory conditions and supports its use as an approach to adding more data to functional assays and improve the relevance of in vitro models for IBD.